RxDoctor Payments Data

Miguel Portocarrero, MD

Nephrology · Kissimmee, FLNPI 1437284049

Payments from drug & device makers

$11,119in general payments, 2019–2025

Across 501 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Vifor Pharma, Inc.$1K
  • Calliditas Therapeutics US Inc.$813
  • Bayer$600
  • plus $5K from 30 others

What the payments were for

  • Food & beverage$10,51895%
  • Education$6015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,119 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$248,611
Medicare patients
539
Services billed
2,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol480$540,636
JardianceEmpagliflozin180$235,980
KerendiaFinerenone62$75,272
SamscaTolvaptan12$49,197
VeltassaPatiromer Calcium Sorbitex18$46,426
LokelmaSodium Zirconium Cyclosilicate13$24,945
DapagliflozinDapagliflozin Propanediol20$14,709
Sevelamer Carbonate28$5,998
Calcitriol154$3,915
Potassium Citrate ErPotassium Citrate29$3,010
SpsSodium Polystyrene Sulfon/Sorb21$1,928
Torsemide74$1,726
Losartan Potassium229$1,648
Cinacalcet Hcl18$1,297
Allopurinol122$1,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,581$565,582493 claims
Boehringer IngelheimJardiance$386$235,980180 claims
BayerKerendia$600$75,27262 claims
Otsuka Pharmaceutical Development & Commercialization, Inc.Samsca$29$49,19712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.

Other nephrology in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →